Member Joanne Hawana was quoted in a Reuters article about the FDA’s plans to restrict GLP-1 ingredients in non-approved compound drugs. The article reports on the agency’s potential enforcement actions involving Hims & Hers and broader regulatory scrutiny of compounded weight-loss medications.

Joanne commented in the article about how the FDA's enforcement actions against Hims could include sending a warning letter, pursuing a court injunction or conducting an administrative seizure of products. The FDA's statements suggest that "this announcement by Hims, to the government, is concerning enough that they decided they’re going to escalate,” she said. 
 

Source

Reuters